**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 70949

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

***In vitro* induced pluripotency from urine-derived cells in porcine**

Recchia K *et al*. Reprogramming urine derived cells in swine

Kaiana Recchia, Lucas Simões Machado, Ramon Cesar Botigelli, Naira Caroline Godoy Pieri, Gabriela Barbosa, Raquel Vasconcelos Guimarães de Castro, Mariana Groke Marques, Laís Vicari de Figueiredo Pessôa, Paulo Fantinato Neto, Flávio Vieira Meirelles, Aline Fernanda de Souza, Simone Maria Massami Kitamura Martins, Fabiana Fernandes Bressan

**Kaiana Recchia, Lucas Simões Machado, Flávio Vieira Meirelles, Fabiana Fernandes Bressan,** Department of Surgery, Faculty of Veterinary Medicine and Animal Sciences, University of São Paulo, Pirassununga 13635-000, São Paulo, Brazil

**Ramon Cesar Botigelli,** Department of Pharmacology and Biotechnology, Institute of Bioscience, São Paulo State University, Botucatu 18618-689, São Paulo, Brazil

**Naira Caroline Godoy Pieri, Gabriela Barbosa, Raquel Vasconcelos Guimarães de Castro, Laís Vicari de Figueiredo Pessôa, Paulo Fantinato Neto, Flávio Vieira Meirelles, Aline Fernanda de Souza, Fabiana Fernandes Bressan,** Department of Veterinary Medicine, Faculty of Animal Sciences and Food Engineering, University of São Paulo, Pirassununga 13635-000, São Paulo, Brazil

**Mariana Groke Marques,** Embrapa Suínos e Aves, Empresa Brasileira de Pesquisa Agropecuária, Concordia 89715-899, Santa Catarina, Brazil

**Simone Maria Massami Kitamura Martins,** Department of Animal Sciences, Faculty of Animal Sciences and Food Engineering, University of São Paulo, Pirassununga 13635-000, São Paulo, Brazil

**Author contributions:** Recchia K and Bressan FF conceptualized the experiments and wrote the manuscript; Recchia K, Machado LS, Barbosa G, Marques MG and Martins SMMK collected and processed samples; Recchia K, Botigelli RC, Pieri NCG, de Castro RVG, Meirelles FV, de Souza AF, Pessôa LVF, Fantinato Neto P and Bressan FF collected data and interpreted the collected data; and all authors revised the manuscript.

**Supported by** the São Paulo Research Foundation (FAPESP) - Brazil (financial support grants #2015/26818-5, #2013/08135-2, #2019/02811-2); Coordination of Superior Level Staff Improvement (CAPES 23038.006964/2014-43 and financial code 001) and National Council for Scientific and Technological Development (CNPq 433133/2018-0).

**Corresponding author: Fabiana Fernandes Bressan, DVM, Professor,** Department of Surgery, Faculty of Veterinary Medicine and Animal Sciences, University of São Paulo, Av Duque de Caxias Norte 225, Pirassununga 13635-000, São Paulo, Brazil. fabianabressan@usp.br

**Received:** August 23, 2021

**Revised:** October 11, 2021

**Accepted: February 15, 2022**

**Published online:**

**Abstract**

BACKGROUND

The generation of induced pluripotent stem cells (iPSC) has been a game-changer in translational and regenerative medicine; however, their large-scale applicability is still hampered by the scarcity of accessible, safe, and reproducible protocols. The porcine model is a large biomedical model that enables translational applications, including gene editing, long term *in vivo* and offspring analysis; therefore, suitable for both medicine and animal production.

AIM

To reprogramme *in vitro* into pluripotency, and herein urine-derived cells (UDCs) were isolated from porcine urine.

METHODS

The UDCs were reprogrammed *in vitro* using human or murine vectors octamer-binding transcription factor 4 (OCT4), SOX2, Kruppel-like factor 4, and C-MYC and cultured with basic fibroblast growth factor (bFGF) supplementation. To characterize the putative porcine iPSCs three clonal lineages were submitted to immunocytochemistry for alkaline phosphatase (AP), OCT4, SOX2, NANOG, TRA1 81 and SSEA 1 detection. Endogenous transcripts related to the pluripotency (OCT4, SOX2 and NANOG) were analyzed *via* reverse transcription quantitative real-time polymerase chain reaction in different time points during the culture, and all three lineages formed embryoid bodies (EBs) when cultured in suspension without bFGF supplementation.

RESULTS

The UDCs were isolated from swine urine samples and when at passage 2 submitted to *in vitro* reprogramming. Colonies of putative iPSCs were obtained only from UDCs transduced with the murine factors (mOSKM), but not from human factors (hOSKM). Three clonal lineages were isolated and further cultured for at least 28 passages, all the lineages were positive for AP detection, the OCT4, SOX2, NANOG markers, albeit the immunocytochemical analysis also revealed heterogeneous phenotypic profiles among lineages and passages for NANOG and SSEA1, similar results were observed in the abundance of the endogenous transcripts related to pluripotent state. All the clonal lineages when cultured in suspension without bFGF were able to form EBs expressing ectoderm and mesoderm layers transcripts.

CONCLUSION

For the first time UDCs were isolated in the swine model and reprogrammed into a pluripotent-like state, enabling new numerous applications in both human or veterinary regenerative medicine.

**Key Words:** Induced pluripotent stem cells; Noninvasive; Pluripotency; Reprogramming; Urine; Porcine

Recchia K, Machado LS, Botigelli RC, Pieri NCG, Barbosa G, de Castro RVG, Marques MG, Pessôa LVF, Fantinato Neto P, Meirelles FV, de Souza AF, Martins SMMK, Bressan FF. *In vitro* induced pluripotency from urine-derived cells in porcine. *World J Stem Cells* 2022; In press

**Core Tip:** The porcine induced pluripotent stem cells (piPSCs) derived from urine derived cells (UDCs) may facilitate their routine and large-scale use by avoiding injury or stress during collection for autologous purposes. However, the precise reprogramming process and characterization is not fully elucidated in other species than murine or human. The generation of piPSCs from UDCs can contribute as a biomedical model for regenerative and translational medicine, as well as for animal production and to elucidate the reprogramming process in porcine, a large animal model.

**INTRODUCTION**

The generation of pluripotent cells *in vitro* has been reported in numerous studies; however, pluripotent cell generation protocols and their characterization are not as robust in animal models as they are in humans and mice. The generation of induced pluripotent stem cells (iPSCs), unlike embryonic stem cells, creates the possibility of autologous therapies and circumvents ethical barriers. iPSCs applications range from basic to applied research, for example, from regenerative medicine to the enhancement of animal production to generate functional gametes or even iPSCs-derived embryos[1-3]. For wild and domestic animal models, the establishment of pluripotent cells and their maintenance *in vitro* may enable diverse translational, clinical and reproductive applications. A robust approach, along with a well-known understanding of the pluripotency pathways for each species, is still to be reported, as previously discussed and reviewed[4-6].

The reprogramming of porcine cells into a pluripotent state can significantly contribute not only to applications in veterinary medicine and animal production, but also, the porcine as a large biomedical model is greatly acknowledged for their physiological and immunological similarities to humans, being suitable to preclinical and translational studies, in special when compared to the murine model[3,5,7-11]. Cells used for the *in vitro* reprogramming into iPSCs are mostly from invasive collection procedures, such as from embryos and interrupted gestations (embryonic and foetal cells), or biopsies (adult fibroblasts and mesenchymal cells)[1,12,13]. The derivation of cultured cells from embryos or foetuses impedes their development, and consequently is considered an unethical practice in humans. The isolation of adult fibroblasts and other tissue-derived cells through biopsies is usual, especially when autologous therapies or *in vitro* modelling of specific genomes is needed. Biopsies, however, usually demand minimally invasive procedures performed by health professionals. Post procedure care may lead to complications such as scars, inflammation, and infection. In particular, the ability of iPSCs to model *in vitro* syndromes or diseases from patients with affected cognitive, neurological, and muscular-skeletal functions may be impaired by such procedures, often requiring special attention and ethics approval. Therefore, using cells from a noninvasive source for the generation of iPSCs would facilitate their use in regenerative and translational human or veterinary medicine, aiming for its large scale use without resulting in injuries or stress[14,15].

Urine-derived cells (UDCs) have been recently reported in humans, and the *in vitro* modelling of diseases using these cells or iPSCs derived from them is increasingly being explored[16,17]. Studies on the *in vitro* differentiation of human UDCs into cardiomyocytes[16] and hepatocyte-like cells[18], the generation of patient-specific iPSC lineages for multiple sclerosis[19], X-linked retinoschisis[20], heart failure[21], phenylketonuria[22], glaucoma[23], and retinitis pigmentosa[24] and, recently, the derivation of iPSCs from UDCs in nonhuman primates[25] reinforce the importance of this recent *in vitro* modelling tool.

Noninvasive cell isolation in domestic animals has also been recently reported from milk[26], an exclusive female possibility, and from urine in the rabbit and canine models[27,28]; however, no pluripotent cells have been derived from these models aiming at its use in regenerative medicine so far. In this context, porcine are nonprimate large animals widely known to present physiological and immunological similarity with humans, as well as they are considered an important species for animal production, with standardized management with pathogen-free conditions[29,30], and consequently, their use as a biomedical model is advantageous compared to nonhuman primates. The fully reprogramming and consistent and robust characterization of porcine iPSCs (piPSCs) are not frequently reported; however, *in vitro* differentiation of these cells into other cell types, and importantly, the generation of chimeras has been presented and discussed, endorsing their use for *in vitro* disease modeling or even for cell therapy[14,18,19,31,32].

Herein, we describe urine collection, cellular isolation, and *in vitro* reprogramming of a noninvasive cell source used for iPSC generation in a large domestic animal, the porcine model. Three clonal lineages were evaluated throughout the passages. Porcine iPSCs derived from UDCs are important not only for agricultural traits, for example, for enabling the *in vitro* generation of gametes and embryos and contributing to future genetic improvement, but also as an excellent platform for the *in vitro* and *in vivo* modelling of several diseases.

**MATERIALS AND METHODS**

All procedures were performed following the National Council for Control of Animal Experimentation (CONCEA) rules and were approvedby the Ethics Committee on Animal Experimentation of the Faculty of Animal Science and Food Engineering and Faculty of Veterinary Medicine and Animal Sciences, University of São Paulo (protocols 6372070119 and 7051150717).

***Urine collection, UDC isolation, and culture***

Swine urine samples (approximately 250 mL) were collected from three females at reproductive age (2 year) after spontaneous urination. The samples were identified as UDC1, UDC2, and UDC3, and processed following the protocol previously described for human samples[33]. Briefly, the urine was aliquoted into conical tubes and centrifuged at 400 × g and 25 °C for 10 min; the supernatant was removed, leaving approximately 1 mL in each tube, washed with 45 mL of D-polybutylene succinate (PBS) (Life Technologies) containing 1% penicillin/streptomycin (Life Technologies), and centrifuged at 200 × g and 25 °C for 10 min. The supernatant was discarded, and the pellet was resuspended in 12 mL of previously prepared medium containing 22.5 mL DMEM high glucose (Life Technologies), 2.5 mL FBS (HyClone), 0.25 mL penicillin/streptomycin (Life Technologies), 0.25 mL 100 × GlutaMAX supplement (Life Technologies), 0.25 mL 100 × nonessential amino acid solution (Life Technologies), 25 mL REBM medium (Renal Epithelial Basal Medium, Lonza) and REGM supplements: 5 μL/mL FBS, hEGF, insulin, hydrocortisone, GA-1000, transferrin, triiodothyronine, epinephrine (all 0.5 μL/mL, Lonza), and basic fibroblast growth factor (bFGF) (2.5 ng/mL, PeproTech).

Cells were plated onto 0.1% gelatine (Sigma-Aldrich)-coated 24-well plates. The medium was replaced at D3 (3rd day after plating) and then partially refreshed every day. The UDC1 cell lineage was further used in the cellular reprogramming protocol, and clonal iPSC lineages were used for statistical analyses.

***In vitro induced reprogramming of porcine UDCs***

*In vitro* reprogramming was performed by transducing UDCs with polycistronic lentiviral vectors harboring either murine or human transcription factors octamer-binding transcription factor 4 (OCT4), SOX2, and KLF-4 C-MYC (mOSKM or hOSKM, STEMCCA-Millipore), as previously reported[34,35]. Briefly, for the production of lentiviral particles, the lipofection protocol (Lipofectamine 3000, Life Technologies) was performed using auxiliary vectors turnaround time, REV, Hgpm2, VSVG, and OSKM in 293 FT cells (Life Technologies) as previously described. UDCs, at a concentration of 2 × 104 per well, were transduced with viral particles and incubated overnight at 38.5 °C, 5% CO2, and maximum humidity for 12-16 h, when media were refreshed.

After 5-6 d, the transduced cells were replaced onto a 6-well plate coated with a monolayer of mitomycin C (M4287 Sigma-Aldrich)-inactivated MEFs and cultured in iPSC medium composed of DMEM/F12 knockout medium supplemented with 20% KSR, 1% glutamine, 3.85 μM β-mercaptoethanol, 1% nonessential amino acids (all from Life Technologies), 10 ng/mL bFGF (PeproTech) and 1% penicillin/streptomycin (Sigma-Aldrich) and incubated at 38.5 °C, 5% CO2 and maximum humidity. After approximately 1 wk, colonies were manually picked at the first passage, and further on, clonal lineages (putative iPSCs, or iPSC-like cells) were dissociated for passaging (TrypLe Express, Life Technologies). Three clonal lineages (C1, C2, and C3) were further analysed throughout passaging. Cryopreservation (20% DMSO), and therefore a freeze-and-thaw cycle, was performed at approximately passage 18 and again at approximately passage 30.

***Reprogramming efficiency and alkaline phosphatase detection***

The reprogramming efficiency was assessed by analysing the ratio of morphologically typical and alkaline phosphatase (AP)-positive iPSCs colonies per the number of transduced cells initially plated (2 × 104 cells per well of a 6-well plate). The AP detection protocol was performed using the Alkaline Phosphatase Detection Kit (86R, Sigma-Aldrich) according to the manufacturer’s instructions.

***Immunocytochemistry***

Immunocytochemistry was used to detect OCT4, SOX2, NANOG, SSEA1, and TRA1 81 in two different passage windows for the three lineages: p16, p15, and p9 for C1, C2, and C3, respectively, and again after p20 (p23, p22, and p22, respectively). The cultured putative piPSCs were fixed in paraformaldehyde for 10 min and washed in PBS. The pluripotency-related markers test was performed as previously described[36]. Briefly, the antibodies were used to detect OCT4 (1:100, cat# SC8628, Santa Cruz), SOX2 (1:500, cat# ab97959; Abcam), NANOG (1:100, cat# ab77095, Abcam), SSEA1 (1:50, cat# MAB4301, Millipore) and TRA1 81 (1:50, cat# MAB4381, Millipore), and the respective secondary antibodies were used (donkey anti-goat 594, cat# A11058, donkey anti-rabbit 488, A21206, 1:500, donkey anti-goat 488, cat# A11055, Invitrogen, 1:500 goat anti-mouse 594, cat# A21044, Invitrogen). When necessary, the cells underwent permeabilization and blocking following previously described methods[37]. At the end of each protocol, the cell nuclei were labelled with Hoechst 33342 (1:1000) and analysed using the EVOS™ photodocumentation system.

***Analysis of endogenous OCT4, SOX2, and NANOG transcripts***

**RNA extraction and reverse transcription:** The specific expression of endogenous factors OCT4, SOX2, NANOG, and exogenous reprogramming factors (mOSKM) was evaluated in UDCs and reprogrammed cells. Additionally, porcine embryos were collected on day 5 after insemination and cultured *in vitro* for 24 h to obtain blastocysts[38]. A pool of 20 porcine blastocysts was used as a positive technical control for pluripotency-related gene expression.

UDCs and iPSCs were recovered from culture plates and centrifuged in microtubes. The pellets were resuspended in linear acrylamide (0.05 mg/mL, Ambion) and UltraPure™ DNase/RNase-Free Distilled Water (Invitrogen), and RNA was extracted using TRIzol Reagent (Invitrogen) following the manufacturer’s instructions. The RNA samples were analyzed regarding quantity and quality using a spectrophotometer (Nanodrop 2000). Reverse transcription of the extracted RNA was performed using the commercial High-Capacity cDNA Reverse Transcription Kit (QIAGEN) according to the manufacturer’s instructions.

**Gene expression quantification:** The three reprogrammed clonal lineages (C1, C2, and C3) were analysed for the expression of the endogenous factors OCT4, SOX2, and NANOG as well as exogenous reprogramming factors (mOSKM) at different time points of *in vitro* culture: Early passages (EP: 15 to 18), intermediate passages (IP: 20 to 24), and late passages (LP: 29 to 32). To quantitatively evaluate expression, primers were designed using Primer-BLAST software (NCBI) with GenBank sequences (Supplementary Table 1). Polymerase chain reaction (PCR) products were sequenced for specificity analysis. The reference genes were glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta-actin 3 (β-ACTIN-3) and normalization was performed based on their geometric means. The primers for endogenous pluripotency gene expression were designed to detect porcine and not murine transcripts, whereas exogenous expression was detected using the mOSKM primers.

Relative expression of candidate genes was quantified by SYBRGreen PCR Master Mix (Life Technologies) using the QuantStudio 5 PCR System (Thermo Fisher). Cycling conditions for amplification were 95 °C for 15 min; 40 cycles of 95 °C for 15 s, 60 °C for 5 s, and 72 °C for 30 s; and 72 °C for 2 min; the melting curve was analysed up to 90 cycles starting at 50 °C with a 0.5 °C increase. The three clonal lineages were considered biological triplicates when compared to UDCs, whereas different passages from the same lineage were considered biological triplicates when these were compared, and all reactions were performed in technical duplicates. The relative gene abundance was performed by 2ΔCT[39].

***Embryoid body assay***

The piPSCLCs from the three lineages at passages 15-16 and also at passages 24-25 were replated into a 6-well plate previously treated with 0.6% agarose and cultured in bFGF-free iPSC medium for 48 to 60 h. The embryoid bodies (EBs) were collected and centrifuged at 900 × g for 5 min, and RNA extraction was performed as described before. Reverse transcription was performed using the commercial High-Capacity cDNA Reverse Transcription Kit (Qiagen) according to the manufacturer’s instructions to evaluate the expression of endodermal (AFP), mesodermal (VIMENTIN and BMP4), and ectodermal (β-TUBULIN III) genes by reverse transcription quantitative real-time PCR (RT-qPCR), as described before (Supplementary Table 1).

***Statistical analysis***

Data obtained from the experimental procedures were analyzed using the statistical program Statistical Analysis System (SAS University Edition), with previous verification of the normality of the residues by the Shapiro-Wilk test (PROC UNIVARIATE). The variables that did not meet the statistical assumptions were submitted to a logarithmic transformation [Log (X + 1)]. The original or transformed data, when necessary, were submitted to analysis of variance. When significant with the variance analysis, the data related to the different cell lineages were submitted to the Bonferroni test. A significance level of 5% was considered for all statistical analyses.

**RESULTS**

***UDC isolation and culture***

Cells isolated from urine first appeared resembling epithelial-like colonies at 3 to 5 d post isolation and then acquired fibroblastic morphology after passaging (Figure 1).

***In vitro induced reprogramming of porcine UDCs***

Cellular reprogramming was performed using murine (mOSKM) or human (hOSKM) polycistronic lentiviral vectors. The transduced cells were evaluated for morphological alterations, and twelve days after transduction, typical colonies were observed and tested for AP presence.

Reprogramming efficiency was assessed by analysing the ratio of typical AP-positive iPSC colonies per number of cells initially plated for transduction (Figure 2 and Supplementary Table 2). Reprogramming with the hOSKM vector presented an initial efficiency of 2.46%; however, the cells did not maintain typical colonies after passage 5 under our culture conditions (cells underwent spontaneous differentiation). Hence, experimentation with hOSKM-derived iPSCs was discontinued. mOSKM presented 3.37% initial reprogramming efficiency, and colonies isolated and further characterized herein maintained a typical morphology and AP expression pattern (Figure 2).

Eight colonies were chosen, manually picked, and replated onto new MEFs to obtain clonal lineages. Three clonal lineages designated as C1, C2, and C3 were remained in the culture at least 28 passages and were positive for AP, however, C2 colonies spontaneously differentiated after 28 passages, and the colonies C1 and C3 were further remained in culture for at least 30 passages.

***Immunocytochemistry***

The clonal lineages were tested in two distinct passaging windows: Between p9 and p16 (p16, p15, and p9, respectively, for C1, C2 and C3) and after p20 (p23, p22, and p22, respectively), enabling analysis among colonies and between culture periods. Cell lineages at p9-16 were positive for OCT4, SOX2, and NANOG and generally negative for SSEA1 and TRA1 81. The C3 (p9) clonal lineage presented some cells positive for SSEA1 and TRA1 81 (Figure 3 and Supplementary Table 3).

In passages > p20, detection of OCT4 and SOX2 was observed, and some cells were also positive for SSEA1. C1 and C2 were negative for NANOG and TRA1 81; however, C3 cells presented mild positivity for both NANOG and TRA1 81 (Figure 3). The results are summarized in Supplementary Table 3.

***RT-qPCR analysis***

As expected, mOSKM was not amplified in UDCs or blastocysts; and endogenous genes were expressed in blastocysts (Figure 4). Then, reprogrammed lineages were compared to each other and the analysis of the expression of endogenous OCT4, SOX2, NANOG, and mOSKM in the different lineages (C1, C2, and C3) revealed that exogenous reprogramming factors were still detected in later passages of iPSCLCs. C3 showed higher expression of the exogenous vector (*P* < 0.0001) and lower expression of SOX2 than lineage C1 (*P* = 0.0099). OCT4 and NANOG expression did not differ among lineages (Figure 5 and Supplementary Table 4).

The analysis of the effect of time in culture (passaging) of the endogenous gene expression in UDCs and the iPSCLCs different groups (EP: 15 to 18; IP: 20 to 24; and LP: 29 to 32) revealed that IP and LP presented higher expression of SOX2, augmenting during culture period; and OCT4 levels were detected in all periods, differing from UDCs. The expression of the exogenous vector did not differ among passages. NANOG expression, however, decreased in intermediate passages, possibly due to a freeze-thaw cycle between EP and IP *in vitro*. At LP, NANOG was again slightly increased. The LP group of the C2 Lineage was not shown once these cells underwent spontaneous differentiation at passage 28 (Supplementary Table 5 and Figure 6).

***Embryoid body assay***

All clonal lineages were replated as single cells onto a nonadherent plate without bFGF supplementation, and these cells formed EBs with typical morphology at different passages (Figure 7). The expression of VIMENTIN, BMP4 and β-TUBULIN-III was detected in the EBs (Figure 8), and AFP was not detected in our conditions (data not shown).

**DISCUSSION**

Herein, cells derived from urine sample (UDCs) were *in vitro* reprogrammed in a large domestic animal model, the swine. Previous studies on porcine have mostly derived iPSCs from foetal or adult fibroblasts, and fewer with multipotent adult cells[1]. UDC-derived piPSCs are highly advantageous for veterinary and regenerative medicine due to the simple collection procedure, avoiding stress or injuries, and in addition, is an inexpensive procedure unlike surgeries aiming biopsies, also important for the feasibility of large-scale sample collection[14,15,17,27,40].

Raab *et al*[40] reported a higher reprogramming efficiency of human UDCs when compared with other somatic cell types. Indeed, several studies have reported cell heterogeneity from urine-derive cells in human, including renal tubular cells[41], urine-stem cells (renal progenitor cells)[42], and urine-derived epithelial cells[16]. It is already known the cells’ origin can influence the reprogramming process, and a more complete characterization and sorting for each cell type prior to reprogramming may be essential to understand the contribution of each cell population to the generation of iPSCs[35,43].

In recent years, it has been showed by several reports the establishment of pluripotency, or at least a state similar to embryonic pluripotency, in several species other than human and mice, and although the main molecular mechanisms involved in pluripotency acquisition *in vitro* are considered rather conserved between species, there are notable differences between species turning the generation of bonafide iPSCs challenging, however still extremely promising.

Indeed, the same human/mouse protocols for iPSCs generation are not extendable to other species[1,3]. Herein we used a previous strategy already reported for large animals reprogramming[34-36,43-45], and widely used to reprogram porcine somatic cells[1]. In the conditions described, the results showed that UDCs transduced with human factors failed to be maintained in culture for more than 5 passages due to early differentiation of the cells cultured *in vitro*, and similar results was described by Pieri *et al*[36] when reprogramming of porcine foetal fibroblasts. Conversely, cells transduced with murine factors were maintained in culture for at least 28 passages, showing typical morphology, positive AP detection and endogenous pluripotency-related gene expression through the different passages. Next steps to improve *in vitro* reprogramming must consider possible epigenetic modulation or even the identification of species-specific pluripotency pathways to improve the nonintegrative reprogramming.

Lineages at p9-16 were positive for SSEA1 and weakly positive for NANOG. These results correlate with a decrease in NANOG expression at IPs, and it might be an effect associated with the freeze-and-thaw process, which was performed in the lineages between EP and IP in this study. Interestingly, the abundance of NANOG transcription increased between the IP and LP. Li *et al*[12] reported that the staining for NANOG, SOX2 and OCT4, increased at passage 20 when compared to p10, indicating a stabilization of the pluripotency phenotype of intermediate type piPSCs. In addition, an elegant discussion was provided by Yamanaka[46] on the heterogeneous profile of each iPSCs lineage, leading to different phenotypes. Furthermore, in our conditions, we infer that a longer time in culture without the freeze-and-thaw process may lead to better reprogramming, as observed by the late acquisition of the SSEA1+ phenotype, a reported marker for human naïve stem cells[47].

All lineages formed EBs that expressed VIMENTIN, BMP4 and b-TUBULIN-III, known markers of mesodermal and ectodermal lineages, respectively. However, none of the EBs presented AFP transcripts, a marker of the endodermal lineage. Rodríguez et al[41] has shown that EBs differentiated from piPSCs cultured in different conditions have shown mesoderm, endoderm and ectoderm markers after 15 d of undirected differentiation, and moreover, some markers not or mildly found at D15, were shown after D30 of differentiation[41]. Hence, further markers and other periods during spontaneous differentiation should be tested for complete characterization and discussion.

Overall, the results presented describe novel ways to derive *in vitro* reprogrammed cells in an important biomedical model, the porcine model. The isolation of UDCs is also relevant for other reproductive technologies, for example, for the conservation of many mammal species through nuclear reprogramming, or even to produce *in vitro* viable gametes, which could decrease the interval between generations for the acquisition of a genetically superior herd. Although the scenario of complete and robust *in vitro* cellular reprogramming is still under discussion in the porcine model; the advances described herein, in our conditions, are valuable for both translational studies and animal production, hence these putative piPSCs can be used to enable future autologous therapies, to the creation of gene-edited or not *in vitro* and *in vivo* biomedical models, to the study of the mechanism of cell differentiation, and also to future generation of gamete- or embryos-derived from iPSCs, contributing to the conservation and propagation of genetic material.

**CONCLUSION**

The results presented herein report, for the first time, the isolation and reprogramming of cells derived through the noninvasive collection of urine in a porcine model. Under our conditions, three putative iPSC lineages generated with murine OSKM presented typical morphology, AP and endogenous pluripotency-related gene expression, which was analyzed in three different passaging periods of the *in vitro* culture, and two lineages were maintained *in vitro* for more than 28 passages. Further studies on pluripotency induction in domestic animals are still needed to thoroughly understand and achieve full reprogramming, including more complete molecular profiles during *in vitro* and *in vivo* reprogramming processes, representing a novel tool for biomedical models of regenerative and translational medicine and animal production improvement.

**ARTICLE HIGHLIGHTS**

***Research background***

Induced pluripotent stem cells (iPSCs) derived from large animal models can greatly contribute to translational medicine and also to animal production, although robust and safe protocols are still uncommon. Cellular reprogramming of urine derived cells presents great advantages for iPSCs use in regenerative medicine due to the easy collection, injury and stress free, and is herein described for the first time in large animals.

***Research motivation***

The porcine iPSCs generation is promising for both translational medicine and animal production; and iPSCs derived from a noninvasive cell source would greatly contribute to its large-scale use, especially for *in vivo* autologous purposes using large animal models.

***Research objectives***

Isolate cells from porcine urine and generate iPSCs through their transduction with Yamanaka’s human or murine factors.

***Research methods***

We isolated urine-derived cells (UDCs), which were reprogrammed *in vitro* into pluripotent cells. The porcine induced pluripotent cells generated were investigated regarding morphology, markers and endogenous transcripts related to the pluripotency.

***Research results***

From the porcine urine samples we isolated the UDCs, and colonies were formed when murine factors were used in the reprogramming. Endogenous pluripotent markers were detected in all three isolated lineages, in different time points during *in vitro* culture, and were able to differentiate into embryoid bodies (EBs) with mesoderm and ectoderm transcripts.

***Research conclusions***

In an unprecedented way, UDCs were isolated from noninvasive collection and reprogrammed into a pluripotent state using murine factors, the cells formed colonies presenting the expected characteristics, such as colonies with limited borders, transcripts and markers related to the pluripotency, and ability to differentiate into EBs.

***Research perspectives***

As we reported here, iPSCs can be derived from an easy collection and noninvasive source in the porcine model, and with our methodology represents a novel tool for iPSCs production in large animals and biomedical models of regenerative or translational medicine.

**ACKNOWLEDGEMENTS**

The authors would like to acknowledge Professors José Eduardo Krieger, Clara Steichen, and Carlos Eduardo Ambrosio for scientific discussion.

**REFERENCES**

1 **Pessôa LVF**, Bressan FF, Freude KK. Induced pluripotent stem cells throughout the animal kingdom: Availability and applications. *World J Stem Cells* 2019; **11**: 491-505 [PMID: 31523369 DOI: 10.4252/wjsc.v11.i8.491]

2 **Sierra H**, Cordova M, Chen CJ, Rajadhyaksha M. Confocal imaging-guided laser ablation of basal cell carcinomas: an ex vivo study. *J Invest Dermatol* 2015; **135**: 612-615 [PMID: 25178106 DOI: 10.1038/jid.2014.371]

3 **Pieri NCG**, de Souza AF, Botigelli RC, Machado LS, Ambrosio CE, Dos Santos Martins D, de Andrade AFC, Meirelles FV, Hyttel P, Bressan FF. Stem cells on regenerative and reproductive science in domestic animals. *Vet Res Commun* 2019; **43**: 7-16 [PMID: 30656543 DOI: 10.1007/s11259-019-9744-6]

4 **Kitala D**, Maurício AC. Novel Perspectives of Stem Cell Manufacturing and Therapies. In: Vicari de Figueiredo Pessôa L, Caroline Godoy Pieri N, Recchia K, Fernandes Bressan F. Induced Pluripotent Stem Cells from Animal Models: Applications on Translational Research. 2020

5 **Nowak-Imialek M**, Kues W, Carnwath JW, Niemann H. Pluripotent stem cells and reprogrammed cells in farm animals. *Microsc Microanal* 2011; **17**: 474-497 [PMID: 21682936 DOI: 10.1017/S1431927611000080]

6 **Bogliotti YS**, Wu J, Vilarino M, Okamura D, Soto DA, Zhong C, Sakurai M, Sampaio RV, Suzuki K, Izpisua Belmonte JC, Ross PJ. Efficient derivation of stable primed pluripotent embryonic stem cells from bovine blastocysts. *Proc Natl Acad Sci U S A* 2018; **115**: 2090-2095 [PMID: 29440377 DOI: 10.1073/pnas.1716161115]

7 **Perin EC**, Miller LW, Taylor DA, Willerson JT. Stem Cell and Gene Therapy for Cardiovascular Disease. In: Migliati E. Large Animal Models for Cardiac Cell Therapy. New York: Elsevier, 2015: 25-36

8 **Cong X**, Zhang SM, Ellis MW, Luo J. Large Animal Models for the Clinical Application of Human Induced Pluripotent Stem Cells. *Stem Cells Dev* 2019; **28**: 1288-1298 [PMID: 31359827 DOI: 10.1089/scd.2019.0136]

9 **Su Y**, Zhu J, Salman S, Tang Y. Induced pluripotent stem cells from farm animals. *J Anim Sci* 2020; **98** [PMID: 33098420 DOI: 10.1093/jas/skaa343]

10 **Cooper DKC**, Hara H, Iwase H, Yamamoto T, Jagdale A, Kumar V, Mannon RB, Hanaway MJ, Anderson DJ, Eckhoff DE. Clinical Pig Kidney Xenotransplantation: How Close Are We? *J Am Soc Nephrol* 2020; **31**: 12-21 [PMID: 31792154 DOI: 10.1681/ASN.2019070651]

11 **Ellis CE**, Korbutt GS. Justifying clinical trials for porcine islet xenotransplantation. *Xenotransplantation* 2015; **22**: 336-344 [PMID: 26381492 DOI: 10.1111/xen.12196]

12 **Li D**, Secher J, Hyttel P, Ivask M, Kolko M, Hall VJ, Freude KK. Generation of transgene-free porcine intermediate type induced pluripotent stem cells. *Cell Cycle* 2018; **17**: 2547-2563 [PMID: 30457474 DOI: 10.1080/15384101.2018.1548790]

13 **Esteban MA**, Xu J, Yang J, Peng M, Qin D, Li W, Jiang Z, Chen J, Deng K, Zhong M, Cai J, Lai L, Pei D. Generation of induced pluripotent stem cell lines from Tibetan miniature pig. *J Biol Chem* 2009; **284**: 17634-17640 [PMID: 19376775 DOI: 10.1074/jbc.M109.008938]

14 **Gao P**, Jiang D, Liu W, Li H, Li Z. Urine-derived Stem Cells, A New Source of Seed Cells for Tissue Engineering. *Curr Stem Cell Res Ther* 2016; **11**: 547-553 [PMID: 25697496 DOI: 10.2174/1574888X10666150220161506]

15 **Ji X**, Wang M, Chen F, Zhou J. Urine-Derived Stem Cells: The Present and the Future. *Stem Cells Int* 2017; **2017**: 4378947 [PMID: 29250119 DOI: 10.1155/2017/4378947]

16 **Jiang YF**, Chen M, Zhang NN, Yang HJ, Rui Q, Zhou YF. *In vitro* and *in vivo* differentiation of induced pluripotent stem cells generated from urine-derived cells into cardiomyocytes. *Biol Open* 2018; **7** [PMID: 29212797 DOI: 10.1242/bio.029157]

17 **Bento G**, Shafigullina AK, Rizvanov AA, Sardão VA, Macedo MP, Oliveira PJ. Urine-Derived Stem Cells: Applications in Regenerative and Predictive Medicine. *Cells* 2020; **9** [PMID: 32121221 DOI: 10.3390/cells9030573]

18 **Zhou M**, Shen L, Qiao Y, Sun Z. Inducing differentiation of human urine-derived stem cells into hepatocyte-like cells by coculturing with human hepatocyte L02 cells. *J Cell Biochem* 2020; **121**: 566-573 [PMID: 31407401 DOI: 10.1002/jcb.29301]

19 **Massa MG**, Gisevius B, Hirschberg S, Hinz L, Schmidt M, Gold R, Prochnow N, Haghikia A. Multiple Sclerosis Patient-Specific Primary Neurons Differentiated from Urinary Renal Epithelial Cells via Induced Pluripotent Stem Cells. *PLoS One* 2016; **11**: e0155274 [PMID: 27158987 DOI: 10.1371/journal.pone.0155274]

20 **Yan X**, Guo Y, Chen J, Cui Z, Gu J, Wang Y, Mao S, Ding C, Chen J, Tang S. Establishment of CSUASOi001-A, a non-integrated induced pluripotent stem cell line from urine-derived cells of a Chinese patient carrying RS1 gene mutation. *Stem Cell Res* 2019; **38**: 101466 [PMID: 31141763 DOI: 10.1016/j.scr.2019.101466]

21 **Cao Y**, Xu J, Wen J, Ma X, Liu F, Li Y, Chen W, Sun L, Wu Y, Li S, Li J, Huang G. Generation of a Urine-Derived Ips Cell Line from a Patient with a Ventricular Septal Defect and Heart Failure and the Robust Differentiation of These Cells to Cardiomyocytes via Small Molecules. *Cell Physiol Biochem* 2018; **50**: 538-551 [PMID: 30308486 DOI: 10.1159/000494167]

22 **Qi Z**, Cui Y, Shi L, Luan J, Zhou X, Han J. Generation of urine-derived induced pluripotent stem cells from a patient with phenylketonuria. *Intractable Rare Dis Res* 2018; **7**: 87-93 [PMID: 29862149 DOI: 10.5582/irdr.2018.01032]

23 **Zhang J**, Wu S, Hu M, Liu Q. Generation of a human induced pluripotent stem cell line from urinary cells of a patient with primary congenital glaucoma using integration free Sendai technology. *Stem Cell Res* 2018; **29**: 162-165 [PMID: 29677590 DOI: 10.1016/j.scr.2018.04.004]

24 **Guo Y**, Zeng Q, Liu S, Yu Q, Wang P, Ma H, Shi S, Yan X, Cui Z, Xie M, Xue Y, Zha Q, Li Z, Zhang J, Tang S, Chen J. Generation of an iPS cell line via a non-integrative method using urine-derived cells from a patient with USH2A-associated retinitis pigmentosa. *Stem Cell Res* 2018; **29**: 139-142 [PMID: 29660607 DOI: 10.1016/j.scr.2018.03.022]

25 **Geuder J**, Wange LE, Janjic A, Radmer J, Janssen P, Bagnoli JW, Müller S, Kaul A, Ohnuki M, Enard W. A non-invasive method to generate induced pluripotent stem cells from primate urine. *Sci Rep* 2021; **11**: 3516 [PMID: 33568724 DOI: 10.1038/s41598-021-82883-0]

26 **Pipino C**, Mandatori D, Buccella F, Lanuti P, Preziuso A, Castellani F, Grotta L, Di Tomo P, Marchetti S, Di Pietro N, Cichelli A, Pandolfi A, Martino G. Identification and Characterization of a Stem Cell-Like Population in Bovine Milk: A Potential New Source for Regenerative Medicine in Veterinary. *Stem Cells Dev* 2018; **27**: 1587-1597 [PMID: 30142991 DOI: 10.1089/scd.2018.0114]

27 **Yang H**, Chen B, Deng J, Zhuang G, Wu S, Liu G, Deng C, Yang G, Qiu X, Wei P, Wang X, Zhang Y. Characterization of rabbit urine-derived stem cells for potential application in lower urinary tract tissue regeneration. *Cell Tissue Res* 2018; **374**: 303-315 [PMID: 30066105 DOI: 10.1007/s00441-018-2885-z]

28 **Xu Y**, Zhang T, Chen Y, Shi Q, Li M, Qin T, Hu J, Lu H, Liu J, Chen C. Isolation and Characterization of Multipotent Canine Urine-Derived Stem Cells. *Stem Cells Int* 2020; **2020**: 8894449 [PMID: 33061993 DOI: 10.1155/2020/8894449]

29 **Du X**, Feng T, Yu D, Wu Y, Zou H, Ma S, Feng C, Huang Y, Ouyang H, Hu X, Pan D, Li N, Wu S. Barriers for Deriving Transgene-Free Pig iPS Cells with Episomal Vectors. *Stem Cells* 2015; **33**: 3228-3238 [PMID: 26138940 DOI: 10.1002/stem.2089]

30 **Perleberg C**, Kind A, Schnieke A. Genetically engineered pigs as models for human disease. *Dis Model Mech* 2018; **11** [PMID: 29419487 DOI: 10.1242/dmm.030783]

31 **Wang H**, Xiang J, Zhang W, Li J, Wei Q, Zhong L, Ouyang H, Han J. Induction of Germ Cell-like Cells from Porcine Induced Pluripotent Stem Cells. *Sci Rep* 2016; **6**: 27256 [PMID: 27264660 DOI: 10.1038/srep27256]

32 **West FD**, Terlouw SL, Kwon DJ, Mumaw JL, Dhara SK, Hasneen K, Dobrinsky JR, Stice SL. Porcine induced pluripotent stem cells produce chimeric offspring. *Stem Cells Dev* 2010; **19**: 1211-1220 [PMID: 20380514 DOI: 10.1089/scd.2009.0458]

33 **Steichen C**, Si-Tayeb K, Wulkan F, Crestani T, Rosas G, Dariolli R, Pereira AC, Krieger JE. Human Induced Pluripotent Stem (hiPS) Cells from Urine Samples: A Non-Integrative and Feeder-Free Reprogramming Strategy. *Curr Protoc Hum Genet* 2017; **92**: 21.7.1-21.7.22 [PMID: 28075482 DOI: 10.1002/cphg.26]

34 **Machado LS**, Pieri NCG, Botigelli RC, de Castro RVG, de Souza AF, Bridi A, Lima MA, Fantinato Neto P, Pessôa LVF, Martins SMMK, De Andrade AFC, Freude KK, Bressan FF. Generation of neural progenitor cells from porcine-induced pluripotent stem cells. *J Tissue Eng Regen Med* 2020; **14**: 1880-1891 [PMID: 33049106 DOI: 10.1002/term.3143]

35 **Bressan FF**, Bassanezze V, de Figueiredo Pessôa LV, Sacramento CB, Malta TM, Kashima S, Fantinato Neto P, Strefezzi RF, Pieri NCG, Krieger JE, Covas DT, Meirelles FV. Generation of induced pluripotent stem cells from large domestic animals. *Stem Cell Res Ther* 2020; **11**: 247 [PMID: 32586372 DOI: 10.1186/s13287-020-01716-5]

36 **Pieri NCG**, de Souza AF, Botigelli RC, Pessôa LVF, Recchia K, Machado LS, Glória MH, de Castro RVG, Leal DF, Fantinato Neto P, Martins SMMK, Dos Santos Martins D, Bressan FF, de Andrade AFC. Porcine Primordial Germ Cell-Like Cells Generated from Induced Pluripotent Stem Cells Under Different Culture Conditions. *Stem Cell Rev Rep* 2021 [PMID: 34115317 DOI: 10.1007/s12015-021-10198-8]

37 **de Souza AF**, Pieri NCG, Roballo KCS, Bressan FF, Casals JB, Ambrósio CE, Perecin F, Martins DS. Dynamics of male canine germ cell development. *PLoS One* 2018; **13**: e0193026 [PMID: 29489867 DOI: 10.1371/journal.pone.0193026]

38 **Marques MG**, de Souza AP, Pandolfi JRC. Metodologia para coleta in vitro de embriões em suínos. 2019

39 **Livak KJ**, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001; **25**: 402-408 [PMID: 11846609 DOI: 10.1006/meth.2001.1262]

40 **Raab S**, Klingenstein M, Liebau S, Linta L. A Comparative View on Human Somatic Cell Sources for iPSC Generation. *Stem Cells Int* 2014; **2014**: 768391 [PMID: 25431601 DOI: 10.1155/2014/768391]

41 **Zhou T**, Benda C, Duzinger S, Huang Y, Li X, Li Y, Guo X, Cao G, Chen S, Hao L, Chan YC, Ng KM, Ho JC, Wieser M, Wu J, Redl H, Tse HF, Grillari J, Grillari-Voglauer R, Pei D, Esteban MA. Generation of induced pluripotent stem cells from urine. *J Am Soc Nephrol* 2011; **22**: 1221-1228 [PMID: 21636641 DOI: 10.1681/ASN.2011010106]

42 **Burdeyron P**, Giraud S, Hauet T, Steichen C. Urine-derived stem/progenitor cells: A focus on their characterization and potential. *World J Stem Cells* 2020; **12**: 1080-1096 [PMID: 33178393 DOI: 10.4252/wjsc.v12.i10.1080]

43 **Pessôa LVF**, Pires PRL, Del Collado M, Pieri NCG, Recchia K, Souza AF, Perecin F, da Silveira JC, de Andrade AFC, Ambrosio CE, Bressan FF, Meirelles FV. Generation and miRNA Characterization of Equine Induced Pluripotent Stem Cells Derived from Fetal and Adult Multipotent Tissues. *Stem Cells Int* 2019; **2019**: 1393791 [PMID: 31191664 DOI: 10.1155/2019/1393791]

44 **Bessi BW**, Botigelli RC, Pieri NCG, Machado LS, Cruz JB, de Moraes P, de Souza AF, Recchia K, Barbosa G, de Castro RVG, Nogueira MFG, Bressan FF. Cattle In Vitro Induced Pluripotent Stem Cells Generated and Maintained in 5 or 20% Oxygen and Different Supplementation. *Cells* 2021; **10** [PMID: 34204517 DOI: 10.3390/cells10061531]

45 **de Castro RVG**, Pieri NCG, Fantinato Neto P, Grizendi BM, Dória RGS, Meirelles FV, Smith LC, Garcia JM, Bressan FF. In Vitro Induction of Pluripotency from Equine Fibroblasts in 20% or 5% Oxygen. *Stem Cells Int* 2020; **2020**: 8814989 [PMID: 33456472 DOI: 10.1155/2020/8814989]

46 **Yamanaka S**. Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges. *Cell Stem Cell* 2020; **27**: 523-531 [PMID: 33007237 DOI: 10.1016/j.stem.2020.09.014]

47 **Inada E**, Saitoh I, Kubota N, Iwase Y, Murakami T, Sawami T, Yamasaki Y, Sato M. Increased Expression of Cell Surface SSEA-1 is Closely Associated with Naïve-Like Conversion from Human Deciduous Teeth Dental Pulp Cells-Derived iPS Cells. *Int J Mol Sci* 2019; **20** [PMID: 30987116 DOI: 10.3390/ijms20071651]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Institutional Review Board at Faculty of Veterinary Medicine and Animal Sciences, University of São Paulo.

**Institutional animal care and use committee statement:** All procedures were performed following the National Council for Control of Animal Experimentation (CONCEA) rules and were approvedby the Ethics Committee on Animal Experimentation of the Faculty of Animal Science and Food Engineering and Faculty of Veterinary Medicine and Animal Sciences, University of São Paulo (protocols 6372070119 and 7051150717).

**Conflict-of-interest statement:** The authors declare that there are no conflicts of interest.

**Data sharing statement:** No additional data are available.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** Brazilian Society of Embryo Technologies; International Embryo Technology Society; Colégio Brasileiro de Reprodução Animal; Associação Brasileira de Terapia Celular e Gênica (ABTCel-Gen); International Society for Stem Cell Research; Sociedade Brasileira de Biologia Celular (SBBC).

**Peer-review started:** August 23, 2021

**First decision:** October 3, 2021

**Article in press:**

**Specialty type:** Cell and tissue engineering

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): C, C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Batool SN, Gao YT, Kumar D, Wahid M **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:**


**Figure Legends**




**Figure 1** **Porcine urine-derived cells at passage 4.** After single-cell dissociation, the cells present a fibroblastic morphology but compact cell culture. Scale bar = 400 μM.




**Figure 2** **Urine-derived cells reprogrammed with hOSKM and mOSKM.** A and B: Urine-derived cells (UDCs) reprogrammed with hOSKM, scale bar: 400 μM; C, D, and E: UDCs reprogrammed with mOSKM: C1, scale bar: 400 μM; F: UDCs reprogrammed with mOSKM: C2, scale bar: 400 μM; G: UDCs reprogrammed with mOSKM: C2, scale bar: 200 μM; H: UDCs reprogrammed with mOSKM: C2, scale bar: 400 μM; I, J and K: UDCs reprogrammed with mOSKM: C3, scale bar: 400 μM. Colonies are flat, with well-defined edges and tightly packed cells in the centre. UDC: Urine-derived cell; iPSCs: Induced pluripotent stem cells.




**Figure 3** **Immunofluorescence for SOX2, octamer-binding transcription factor 4, NANOG, SSEA1, and TRA1 81 detection in C1, C2, and C3 at different passages.** Cell lines at p9-16 were positive for octamer-binding transcription factor 4 (OCT4), SOX2, and NANOG and negative for SSEA1 and TRA1 81. C3 presented some cells positive for SSEA1 and TRA1 81. At later passages, OCT4 and SOX2 were observed, and some cells also presented SSEA1. C1 and C2 were negative for NANOG and TRA1 81, while C3 presented a mildly positive detection for both. OCT4: Octamer-binding transcription factor 4; UDC: Urine-derived cell; iPSCs: Induced pluripotent stem cells.




**Figure 4** **Analysis of the expression of endogenous factors octamer-binding transcription factor 4**, **SOX2, NANOG, and exogenous OSKM between** **urine-derived cell and** **induced pluripotent stem cells.** a*P* < 0.05 between urine-derived cells (UDCs) and induced pluripotent stem cells (iPSCs). \*\*Represents gene expression analysis of a pool of D6 porcine blastocysts, which did not integrate statistical analyses. Both endogenous and exogenous reprogramming factors were detected on iPSCs but not on UDCs, and porcine blastocysts presented endogenous pluripotency-related gene expression only. OCT4: Octamer-binding transcription factor 4; UDC: Urine-derived cell; iPSCs: Induced pluripotent stem cells.

****


**Figure 5 Analysis of the expression of endogenous factors octamer-binding transcription factor 4, SOX2, NANOG, and exogenous OSKM in the different lineages (C1, C2, and C3) of induced pluripotent stem cells.** Exogenous reprogramming factors were still detected in later passages. Superscript letters represent differences (*P* < 0.05) between groups. aRepresents higher relative mRNA abundance, brepresents lower relative mRNA abundance when compared to a, and crepresents lower relative mRNA abundance when compared to b. OCT4: Octamer-binding transcription factor 4; UDC: Urine-derived cell.



**Figure 6** **Analysis of endogenous gene expression in urine-derived cell s and the different groups (early passages, intermediate passages, and late passages) of induced pluripotent stem cells**. Exogenous reprogramming factors were still detected in later passages. Superscript letters represent differences (*P* < 0.05) between groups. aRepresents higher relative mRNA abundance, brepresents lower relative mRNA abundance when compared to a, and crepresents lower relative mRNA abundance when compared to b. EP: Early passages; IP: Intermediate passages; LP: Late passages; OCT4: Octamer-binding transcription factor 4; UDC: Urine-derived cell.



**Figure 7** **All three clonal** **induced pluripotent stem cell lineages formed embryoid bodies with typical 3D morphology.** A: Embryoid bodies (EBs) from induced pluripotent stem cells (iPSCs) at passages 15-16 (scale bar = 400 μM); B: EBs from iPSCs at passages 24-15 (scale bar = 400 μM-200 μM). EBs: Embryoid bodies; UDC: Urine-derived cell; iPSCs: Induced pluripotent stem cells.



**Figure 8** **Relative mRNA abundance of urine-derived cells and embryoid bodies derived from the three porcine induced pluripotent stem cells lines showing VIMENTIN, BMP4 and β-TUBULIN-III detection.** Embryoid bodies were analysed when porcine induced pluripotent stem cells were at p15-16 and again at p24-25. UDC: Urine-derived cell.